Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis

Hushaw, Linda; Sawaqed, Ray; Sweis, Ghaleb; Reigle, Jori; Gopal, Anand; Brandt, Daniel; Sweis, Nadia J.; Curran, James F.; Niewold, Timothy B.; Sweiss, Nadera J.

doi:10.2147/tcrm.s5582

Cited by 13 publications

(10 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In human body, the complex of soluble IL-6R and IL-6 forms relying on the mediation of ligand binding receptor protein (80 kD), after which the complex binds non-ligand binding receptor protein to activate the binding of cells to IL-6, thus becoming IL-6-sensitive cells. 11 - 13 In this study, the bloods of ARD patients and normal subjects were collected, which were reacted with same amounts of soluble IL-6 antibody detecting agents for comparison.…”

Section: Discussionmentioning

confidence: 99%

Clinical effects of soluble interleukin-6 receptor detection on autoimmune rheumatic disease patients

Chen

Sun

et al. 2014

Pak J Med Sci

View full text Add to dashboard Cite

Objective : This study aims to explore the effects of soluble interleukin-6 receptor (IL-6R) on the clinical diagnosis and treatment of autoimmune rheumatic disease (ARD) patients. Methods: Sixty-eight ARD patients enrolled in our hospital recently were selected, the IL-6R levels of whom were detected by double-antibody sandwich ELISA method and compared with the IL-6 levels of normal subjects. The expressions of IL-6R in joint tissues were detected by section staining. The mechanism regarding the effects of IL-6R was postulated by administering the patients with blocking agent. Results: The blood IL-6R level of ARD patients was 2-3 times higher than the IL-6 level of normal subjects with significant difference. The detection results of C-reactive protein and erythrocyte sedimentation rate show that both the indicators were significantly decreased (P=0.0098 and 0.0097 respectively). IL-6R was associated with autoimmunity based on the considerable expression in tissue sections, which was also verified by the alleviated symptoms after blocking IL-6R expression. Conclusion: Detecting soluble IL-6R is able to determine the patient's conditions and treatment effects. Meanwhile, soluble IL-6R detection can also serve as the inflammatory responses of ARD, as well as the determination index for abnormal immune responses and generated antibodies number, which is crucial for early diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical effects of soluble interleukin-6 receptor detection on autoimmune rheumatic disease patients

Chen

Sun

et al. 2014

Pak J Med Sci

View full text Add to dashboard Cite

show abstract

“…Важным иммунопатологическим механизмом воспаления при РА является гиперпродукция ИЛ6. Этот цитокин является медиатором не только воспаления и деструкции суставов при РА, но и ряда системных иммунных реакций, таких как лихорадка, анемия, кахексия, амилоидоз [33].…”

Section: клиническое наблюдениеunclassified

Combination of ankylosing spondylitis and rheumatoid arthritis: clinical observations and literature review

Годзенко¹,

Cheremushkina

Димитрева³

et al. 2021

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

The article discusses one of the variants of overlap syndrome – a combination of symptoms of ankylosing spondylitis (AS) and rheumatoid arthritis (RA). Three clinical cases are described, in these cases characteristic signs of both diseases were noted and the criteria of both diseases were met. The genetic factors and immunopathogenetic mechanisms underlying AS and RA are analyzed. A review of the literature on the combination of AS and RA is presented.

show abstract

“…ИЛ6 -провоспалительный цитокин, ключевая роль которого в патогенезе РА доказана [7]. На сегодняшний день зарегистрированы два ГИБП для лечения РА, воздействующие на ИЛ6 путем блокады соответствующего рецептора [8,9]. Несмотря на то, что изучались и другие препараты, также воздействующие непосредственно на ИЛ6, ни один из них не зарегистрирован [10].…”

Section: Introductionunclassified

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study

Feist¹,

Fatenejad

Grishin

et al. 2023

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

Objectives To assess the efficacy and safety of olokizumab (OKZ), a monoclonal antibody against the interleukin-6 (IL-6) cytokine, versus placebo (PBO) in patients with prior inadequate response to tumour necrosis factor inhibitors (TNFi-IRs).Methods In this 24-week multicentre, placebo-controlled, double-blind study, the patients were randomised in a 2:2:1 ratio to receive subcutaneously administered OKZ 64 mg once every 2 weeks (q2w), OKZ 64 mg once every 4 weeks (q4w) or PBO plus methotrexate. At week 16, the patients on PBO were randomised to receive either OKZ regime. The primary endpoint was the proportion of patients achieving an American College of Rheumatology 20% (ACR20) response at week 12. Disease Activity Score 28-joint count C-reactive protein (DAS28 (CRP)) <3.2 at week 12 was the major secondary efficacy endpoint. Safety and immunogenicity were assessed.Results In 368 patients randomised, ACR20 response rates were 60.9% in OKZ q2w, 59.6% in OKZ q4w and 40.6% in PBO (p<0.01 for both comparisons). Achievement of DAS28 (CRP) <3.2 was significantly different, favouring the OKZ arms. Improvements in efficacy and patientreported outcomes were maintained throughout 24 weeks and were noted after week 16 in patients who switched from PBO.Dose-related treatment-emergent serious adverse events were 7% in OKZ q2w, 3.2% in OKZ q4w and none in the PBO group.Conclusions Direct inhibition of IL-6 with OKZ resulted in significant improvements in the signs and symptoms of rheumatoid arthritis compared with PBO in TNFi-IR patients with a similar safety profile as observed for monoclonal antibodies to the IL-6 receptor.

show abstract

Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis

Cited by 13 publications

References 42 publications

Clinical effects of soluble interleukin-6 receptor detection on autoimmune rheumatic disease patients

Clinical effects of soluble interleukin-6 receptor detection on autoimmune rheumatic disease patients

Combination of ankylosing spondylitis and rheumatoid arthritis: clinical observations and literature review

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study

Contact Info

Product

Resources

About